Yamada Kyogo, Sugiyama Yuzuru, Seino Kageyoshi, Kobori Hiroyasu, Ebina Tetsunori, Shibata Shigeru, Kawasaki Hitoshi, Sasaki Mutsuo, Tanaka Masanori
Dept. of Surgery, Public Kanagi Hospital.
Gan To Kagaku Ryoho. 2005 Oct;32(10):1447-51.
TS-1 was introduced into the treatment of advanced or recurrent gastric cancer cases. Along with independent administration of TS-1, a high antitumor effect has been reported in combination with various anticancer agents. We report a patient with gastric cancer successfully treated with TS-1 and low-dose CDDP as neoadjuvant chemotherapy. The patient was a 46-year-old man who was diagnosed as type 3 gastric cancer with suspected invasion of the pancreas. Histopathological findings demonstrated the degeneration of cancer cells and fibrosis in the primary tumor. The changes against neoadjuvant chemotherapy were judged to be Grade 3. The treatment was completed without adverse events. TS-1 and low-dose CDDP therapy can be one of the effective methods as neoadjuvant chemotherapy without remarkable toxicity.
替吉奥（TS-1）已被应用于晚期或复发性胃癌病例的治疗。除单独使用替吉奥外，与多种抗癌药物联合使用时也有较高的抗肿瘤效果报道。我们报告一例胃癌患者，采用替吉奥和低剂量顺铂作为新辅助化疗成功治疗。该患者为一名46岁男性，被诊断为3型胃癌，怀疑侵犯胰腺。组织病理学检查结果显示原发肿瘤癌细胞变性和纤维化。新辅助化疗后的变化判定为3级。治疗过程顺利，未出现不良事件。替吉奥和低剂量顺铂治疗可作为新辅助化疗的有效方法之一，且毒性不明显。
